Literature DB >> 11182240

Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization.

T Arendt1.   

Abstract

Mental function has as its cerebral basis a specific dynamic structure. In particular, cortical and limbic areas involved in "higher brain functions" such as learning, memory, perception, self-awareness and consciousness continuously need to be self-adjusted even after development is completed. By this lifelong self-optimization process, the cognitive, behavioural and emotional reactivity of an individual is stepwise remodelled to meet the environmental demands. While the presence of rigid synaptic connections ensures the stability of the principal characteristics of function, the variable configuration of the flexible synaptic connections determines the unique, non-repeatable character of an experienced mental act. With the increasing need during evolution to organize brain structures of increasing complexity, this process of selective dynamic stabilization and destabilization of synaptic connections becomes more and more important. These mechanisms of structural stabilization and labilization underlying a lifelong synaptic remodelling according to experience, are accompanied, however, by increasing inherent possibilities of failure and may, thus, not only allow for the evolutionary acquisition of "higher brain function" but at the same time provide the basis for a variety of neuropsychiatric disorders. It is the objective of the present paper to outline the hypothesis that it might be the disturbance of structural brain self-organization which, based on both genetic and epigenetic information, constantly "creates" and "re-creates" the brain throughout life, that is the defect that underlies Alzheimer's disease (AD). This hypothesis is, in particular, based on the following lines of evidence. (1) AD is a synaptic disorder. (2) AD is associated with aberrant sprouting at both the presynaptic (axonal) and postsynaptic (dendritic) site. (3) The spatial and temporal distribution of AD pathology follows the pattern of structural neuroplasticity in adulthood, which is a developmental pattern. (4) AD pathology preferentially involves molecules critical for the regulation of modifications of synaptic connections, i.e. "morphoregulatory" molecules that are developmentally controlled, such as growth-inducing and growth-associated molecules, synaptic molecules, adhesion molecules, molecules involved in membrane turnover, cytoskeletal proteins, etc. (5) Life events that place an additional burden on the plastic capacity of the brain or that require a particularly high plastic capacity of the brain might trigger the onset of the disease or might stimulate a more rapid progression of the disease. In other words, they might increase the risk for AD in the sense that they determine when, not whether, one gets AD. (6) AD is associated with a reactivation of developmental programmes that are incompatible with a differentiated cellular background and, therefore, lead to neuronal death. From this hypothesis, it can be predicted that a therapeutic intervention into these pathogenetic mechanisms is a particular challenge as it potentially interferes with those mechanisms that at the same time provide the basis for "higher brain function".

Entities:  

Mesh:

Year:  2001        PMID: 11182240     DOI: 10.1016/s0306-4522(00)00516-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  38 in total

1.  The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.

Authors:  Jean-Marie Sontag; Viyada Nunbhakdi-Craig; Charles L White; Shelley Halpain; Estelle Sontag
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice.

Authors:  Xiao-Xin Yan; Yan Cai; Xue-Mei Zhang; Xue-Gang Luo; Huaibin Cai; Gregory M Rose; Peter R Patrylo
Journal:  Exp Neurol       Date:  2012-01-11       Impact factor: 5.330

Review 3.  Morphological characteristics of apoptosis and its significance in neurogenesis.

Authors:  S G Kalinichenko; N Yu Matveeva
Journal:  Neurosci Behav Physiol       Date:  2008-05

4.  Selective cell death of hyperploid neurons in Alzheimer's disease.

Authors:  Thomas Arendt; Martina K Brückner; Birgit Mosch; Andreas Lösche
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

5.  Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology.

Authors:  Sonia Do Carmo; Gogce Crynen; Tiffany Paradis; Jon Reed; M Florencia Iulita; Adriana Ducatenzeiler; Fiona Crawford; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2017-05-13       Impact factor: 5.590

6.  Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy.

Authors:  Johanna L Crimins; Anne B Rocher; Jennifer I Luebke
Journal:  Acta Neuropathol       Date:  2012-09-14       Impact factor: 17.088

7.  Axonal tract tracing for delineating interacting brain regions: implications for Alzheimer's disease-associated memory.

Authors:  Thomas van Groen; Pasi Miettinen; Inga Kadish
Journal:  Future Neurol       Date:  2014-01-01

Review 8.  The dendritic hypothesis for Alzheimer's disease pathophysiology.

Authors:  J Nicholas Cochran; Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2013-12-12       Impact factor: 4.077

Review 9.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

10.  Attentional performance, impulsivity, and related neurotransmitter systems in apoE2, apoE3, and apoE4 female transgenic mice.

Authors:  Ingrid Reverte; Fiona Peris-Sampedro; Pia Basaure; Leticia Campa; Cristina Suñol; Margarita Moreno; José Luis Domingo; Maria Teresa Colomina
Journal:  Psychopharmacology (Berl)       Date:  2016-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.